Empowering Pharmacists in the Fight Against Opioid Abuse Act

Bill: 114-hr-5314
Sponsor: full_name: Rep. DeSaulnier, Mark [D-CA-11]
Introduced: 2016-05-24
Policy area: Crime and Law Enforcement
Subjects: Drug trafficking and controlled substances

Fraud offenses and financial crimes

Government information and archives

Health personnel

Health promotion and preventive care

Prescription drugs
Latest action: action_date: 2016-05-24
text: Referred to the House Committee on Energy and Commerce.

Summaries:
action_date: 2016-05-24
action_desc: Introduced in House
text: <p><b>Empowering Pharmacists in the Fight Against Opioid Abuse Act</b></p> <p>This bill requires the Drug Enforcement Administration (DEA) to develop and disseminate training programs and materials on: (1) the circumstances under which a pharmacist may refuse to fill a controlled substance prescription suspected to be fraudulent, forged, or indicative of abuse or diversion; and (2) federal requirements related to such refusal.</p> <p>The DEA must seek input from relevant stakeholders.</p>

tv_txt: I 114th CONGRESS 2d Session H. R. 5314 IN THE HOUSE OF REPRESENTATIVES May 24, 2016 Mr. DeSaulnier (for himself and Mr. Carter of Georgia ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To provide for the development and dissemination of programs and materials for training pharmacists, health care providers, and patients on the circumstances under which a pharmacist may decline to fill a prescription for a controlled substance because the pharmacist suspects the prescription is fraudulent, forged, or otherwise indicative of abuse or diversion, and for other purposes.

1. Short title This Act may be cited as the Empowering Pharmacists in the Fight Against Opioid Abuse Act . 2. Programs and materials for training on certain circumstances under which a pharmacist may decline to fill a prescription (a) In general Not later than 1 year after the date of enactment of this Act, the Administrator of the Drug Enforcement Administration, in consultation with the Secretary of Health and Human Services and the Commissioner of Food and Drugs, shall develop and disseminate programs and materials for training pharmacists, health care providers, and patients on— (1) circumstances under which a pharmacist may, consistent with section 201 of the Controlled Substances Act ( 21 U.S.C. 801 et seq. ) and regulations thereunder, including section 1306.04 of title 21, Code of Federal Regulations, decline to fill a prescription for a controlled substance because the pharmacist suspects the prescription is fraudulent, forged, or otherwise indicative of abuse or diversion; and (2) any Federal requirements pertaining to declining to fill a prescription under such circumstances. (b) Stakeholder input In developing the programs and materials required by paragraph (1), the Administrator of the Drug Enforcement Administration shall seek input from relevant national, State, and local associations, boards of pharmacy, medical societies, and licensing boards.